Sie suchten nach: ceftazidima (Slowenisch - Englisch)

odmerek ceftazidima/avibaktama
dose of ceftazidime/avibactam

spekter delovanja ceftazidima/avibaktama
spectrum of activity of ceftazidime/avibactam

podatkov o študijah ceftazidima na živalih ni.
no data are available on animal studies with ceftazidime.

približna koncentracija ceftazidima/avibaktama (mg/ml)
approximate ceftazidime/avibactam concentration (mg/ml)

kloramfenikol je in vitro antagonist ceftazidima in drugih cefalosporinov.
chloramphenicol is antagonistic in vitro with ceftazidime and other cephalosporins.

farmakokinetika ceftazidima pri bolnikih s hudo okvaro jeter ni ugotovljena.
the pharmacokinetics of ceftazidime in patients with severe hepatic impairment has not been established.

koncentracijo ceftazidima v serumu je mogoče zmanjšati s hemodializo ali peritonealno dializo.
serum levels of ceftazidime can be reduced by haemodialysis or peritoneal dialysis.

odstranjevanje ceftazidima in avibaktama je zmanjšano pri bolnikih z zmerno ali hudo okvaro ledvic.
elimination of ceftazidime and avibactam is decreased in patients with moderate or severe renal impairment.

kombinacijo ceftazidima in avibaktama se sme med nosečnostjo uporabiti le, če morebitne koristi upravičujejo možno tveganje.
ceftazidime/avibactam should only be used during pregnancy if the potential benefit outweighs the possible risk.

manj kot 1 % ceftazidima se izloči z žolčem in manj kot 0,25 % avibaktama se izloči v blatu.
less than 1% of ceftazidime is excreted via the bile and less than 0.25% of avibactam is excreted into faeces.

vezava ceftazidima in avibaktama na človeške proteine je približno 10 % za ceftazidim in približno 8 % za avibaktam.
the human protein binding of both ceftazidime and avibactam is approximately 10% and 8%, respectively.

ena viala vsebuje ceftazidim pentahidrat, ki ustreza 2 g ceftazidima, in natrijev avibaktamat, ki ustreza 0,5 g avibaktama.
each vial contains ceftazidime pentahydrate equivalent to 2 g ceftazidime and avibactam sodium equivalent to 0.5 g avibactam.

blaga do zmerna okvara jeter ni vplivala na farmakokinetiko ceftazidima pri osebah, ki so 5 dni prejemale 2 g ceftazidima na 8 ur intravensko in niso imele okvarjenega delovanja ledvic.
mild to moderate hepatic impairment had no effect on the pharmacokinetics of ceftazidime in individuals administered 2 g intravenously every 8 hours for 5 days, provided renal function was not impaired.

po pripravi vsebuje 1 ml raztopine 167,3 mg ceftazidima in 41,8 mg avibaktama (glejte poglavje 6.6).
after reconstitution, 1 ml of solution contains 167.3 mg of ceftazidime and 41.8 mg of avibactam (see section 6.6).

po uporabi intravenskih bolusnih odmerkov 2 g ceftazidima na 12 ur pri bolnikih, starih 80 let ali več, je bil njegov povprečni eliminacijski razpolovni čas od 3,5 do 4 ure.
the mean elimination half-life of ceftazidime ranged from 3.5 to 4 hours following intravenous bolus dosing with 2 g every 12 hours in elderly patients aged 80 years or older.

odločiti se je treba bodisi za prenehanje dojenja bodisi za prekinitev/prenehanje zdravljenja s kombinacijo ceftazidima in avibaktama, upoštevaje korist dojenja za otroka in korist zdravljenja za žensko.
a decision must be made whether to discontinue breast feeding or to discontinue/abstain from ceftazidime/avibactam therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.

Če bolnikom z okvaro ledvic niso zmanjšali odmerka ceftazidima, so med njegovo uporabo občasno poročali o nevroloških posledicah, med drugim o tremorju, mioklonusu, nekonvulzivnem epileptičnem statusu, konvulzijah, encefalopatiji in komi.
neurological sequelae, including tremor, myoclonus, non-convulsive status epilepticus, convulsion, encephalopathy and coma, have occasionally been reported with ceftazidime when the dose has not been reduced in patients with renal impairment.

pri zdravih odraslih, ki so prejeli večkratne odmerke 2000 mg ceftazidima/500 mg avibaktama, infundirane v 2 urah vsakih 8 ur, sta bila njuna volumna porazdelitve v stanju dinamičnega ravnovesja približno 22 l (ceftazidim) in 18 l (avibaktam).
the steady-state volumes of distribution of ceftazidime and avibactam were about 22 l and 18 l, respectively in healthy adults following multiple doses of 2000 mg/500 mg ceftazidime/avibactam infused over 2 hours every 8 hours.